Professor, Neurology, Baylor College of Medicine
Neurology
Dr. Rachelle S. Doody, MD
|
|
Give Review
Rachelle Doody practices Neurology. She researched medicine at Baylor College of Medicine. She has 3 awards "America's Top Doctors", "Top Doctors:SE Texas" and "CMS Meaningful Use Stage 1 Certification". Rachelle Doody has written publications. She has 101 publications published with PubMed. The lastest publication is: 'Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.' Dr. Rachelle S. Doody accepts all Medicare patients.
Publications
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
- Ordered Subset Analysis of Copy Number Variation Association with Age at Onset of Alzheimer's Disease.
- A phase 3 trial of semagacestat for treatment of Alzheimer's Disease.
- Effectiveness of antidementia drugs in delaying Alzheimer's Disease progression.
- Molecular Neuropsychology: Creation of Test-Specific Blood Biomarker Algorithms.
- Genome-wide scan for copy number variation association with age at onset of Alzheimer's Disease.
- Reviewing the role of donepezil in the treatment of Alzheimer's Disease.
- Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: A comparison of item response theory-based scores and total scores.
- Binomial regression with a misclassified covariate and outcome.
- Item Response Theory Reveals Variability of Functional Impairment within Clinical Dementia Rating Scale Stages.
- A blood-based screening tool for Alzheimer''s Disease that spans serum and plasma: findings from TARC and ADNI.
- A blood-based algorithm for the detection of Alzheimer''s Disease.
- Plasma sphingomyelins are associated with cognitive progression in Alzheimer''s Disease.
- Should persons with autosomal dominant AD be included in clinical trials? Authors'' response.
- Identifying amnestic mild cognitive impairment in primary care: a feasibility study.
- Dementia staging across three different methods.
- Olfactory copy number association with age at onset of Alzheimer Disease.
- Global issues in drug development for Alzheimer's Disease.
- Should EOAD patients be included in clinical trials?
- Long-term treatment with lithium alleviates memory deficits and reduces amyloid-β production in an aged Alzheimer's Disease transgenic mouse model.
- Apolipoprotein E polymorphism and age at onset of Alzheimer''s Disease in a quadriethnic sample.
- Report of the task force on designing clinical trials in early (preDementia) AD.
- Clinical trials in AD.
- A serum protein-based algorithm for the detection of Alzheimer Disease.
- Causes of aggressive behavior in patients with Dementia.
- Correction: Predicting progression of Alzheimer''s Disease.
- Evolving early (pre-dementia) Alzheimer''s Disease trials: suit the outcomes to the population and study design.
- Randomized controlled trial of atorvastatin in mild to moderate Alzheimer Disease: LEADe.
- Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study.
- Predicting progression of Alzheimer''s Disease.
- Consequences of aggressive behavior in patients with Dementia.
- Vitamin E use is associated with improved survival in an Alzheimer''s Disease cohort.
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer Disease.
- Donepezil treatment of patients with MCI: a 48-week randomized, placebo- controlled trial.
- Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer Disease.
- Dimebon as a potential therapy for Alzheimer''s Disease.
- How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer''s Disease?
- Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
- Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
- Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer''s Disease: it is time to better integrate pa...
- Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's Disease clinical trials: t...
- A roadmap for the prevention of Dementia II: Leon Thal Symposium 2008.
- Korean version of the Baylor Profound Mental Status Examination: a brief staging measure for patients with severe Alzheimer''s Disease.
- Exploring self-neglect in older adults: preliminary findings of the self-neglect severity scale and next steps.
- Cholinesterase inhibitors and memantine: best practices.
- Alzheimer''s Disease and mild cognitive impairment deteriorate fine movement control.
- Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
- Staging Dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer''s research consortium study.
- Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer''s Disease: a randomised, double...
- A roadmap for the prevention of Dementia: the inaugural Leon Thal Symposium.
- The Atorvastatin/Donepezil in Alzheimer''s Disease Study (LEADe): design and baseline characteristics.
- Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer''s Disease.
- We should not distinguish between symptomatic and Disease-modifying treatments in Alzheimer''s Disease drug development.
- Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to Dementia.
- Disease-modifying therapies for Alzheimer Disease: challenges to early intervention.
- Is functional decline necessary for a diagnosis of Alzheimer''s Disease?
- Donepezil preserves cognition and global function in patients with severe Alzheimer Disease.
- Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with Dementia of the Alzheimer''s type.
- Meta-analysis of six-month memantine trials in Alzheimer's Disease.
- ADCS Prevention Instrument Project: ADCS-clinicians'' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
- Realistic expectations for treatment success in Alzheimer''s Disease.
- Influence of premorbid IQ and education on progression of Alzheimer''s Disease.
- A 24-week open-label extension study of memantine in moderate to severe Alzheimer Disease.
- The making of a self-neglect severity scale.
- Recommendations for best practices in the treatment of Alzheimer's Disease in managed care.
- Survival among patients with Dementia from a large multi-ethnic population.
- Donepezil in vascular Dementia: combined analysis of two large-scale clinical trials.
- Self-reported awareness of performance in Dementia.
- Changing patient characteristics and survival experience in an Alzheimer''s center patient cohort.
- Factors affecting deficit awareness in persons with Dementia.
- Vitamin E and donepezil for the treatment of mild cognitive impairment.
- Refining treatment guidelines in Alzheimer''s Disease.
- Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer Disease.
- Accuracy of self-reported depression in persons with Dementia.
- Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III).
- The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls.
- Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer''s Disease.
- Dementia Deficits Scale. Rating self-awareness of deficits.
- Mild cognitive impairment can be distinguished from Alzheimer Disease and normal aging for clinical trials.
- WAIS-R factor structure in Alzheimer's Disease patients: a comparison of alternative models and an assessment of their generalizability.
- Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed Dementia diagnoses?
- A method for estimating duration of illness in Alzheimer''s Disease.
- Donepezil in vascular Dementia: a randomized, placebo-controlled study.
- Current treatments for Alzheimer''s Disease: cholinesterase inhibitors.
- Memantine in moderate-to-severe Alzheimer''s Disease.
- Effects of blood pressure on neuropsychological functioning in Alzheimer's Disease.
- A videotaped CIBIC for Dementia patients: validity and reliability in a simulated clinical trial.
- Prevalence and incidence of major depressive disorder in Alzheimer''s Disease: findings from two databases.
- Current concepts in mild cognitive impairment.
- A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
- Alzheimer's Disease in long-term care: maximizing treatment options.
- Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer''s Disease.
- Practice parameter: management of Dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
- Cognitive intervention in Alzheimer Disease: a randomized placebo-controlled study.
- A method for estimating progression rates in Alzheimer Disease.
- Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer Disease.
- Mortality from pneumonia and hip fractures in patients with advanced Dementia.
- Does APO epsilon4 correlate with MRI changes in Alzheimer''s Disease?
- Long-term efficacy and safety of donepezil in the treatment of Alzheimer''s Disease: final analysis of a US multicentre open-label study.
- Estrogen replacement therapy for treatment of mild to moderate Alzheimer Disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
Schools
Baylor University
McGill University
Baylor College Of Med
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Dementia
- Epilepsy
- Gait Abnormality
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- CMS Meaningful Use Stage 1 Certification
Education
-
Baylor College of Medicine
Hospital
-
Baylor St. Luke's Medical Center
Drug Facts
| NPI NUMBER | 1457431793 | |
| NPPES Provider LastName | DOODY | |
| NPPES Provider FirstName | RACHELLE | |
| NPPES Provider ZIPCode | 770302717 | |
| NPPES Provider State | TX | |
| Specialty Description | Neurology | |
| Total Claim Count | 1155.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457431793 |
| Last Name Of The Provider | DOODY |
| First Name Of The Provider | RACHELLE |
| View All |
Similar Doctors
|
Dr. Ronald M. Zweighaft, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Sheila W. Jacobson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard T. Hoos, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Suprabha Bhat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose J. Leyva, MD |
|
|
Dr. Margarete Borck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rouzbeh Fateh, MD |
|
|
Dr. Peter W. Johnson, MD |
|
|
Dr. Komal Rastogi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mered Parnes, MD |
|
|
Dr. Jessica L. Stachyra, DO |